Increased vulnerability of the spinal cord to radiation or intrathecal chemotherapy during adolescence: A report from the Children's Oncology Group

Pediatric Blood and Cancer

Volumn 53, Issue 7, 2009, Pages 1205-1210

  Bleyer, Archie ^a,b,c,d   Choi, Mehee ^e   Wang, Samuel J ^b   Fuller, Clifton D ^f,g   Raney, R Beverly ^h  

^a ST CHARLES MEDICAL CENTER   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c CHILDREN S ONCOLOGY GROUP   (United States)

^d CureSearch/National Childhood Cancer Foundation   (United States)

^e MAYO CLINIC   (United States)

^f University of Texas Health Science Center   (United States)

^g UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^h NONE

Author keywords

Adolescence; Intrathecal chemotherapy; Radiation myelopathy; Sarcoma; Spinal cord

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DACTINOMYCIN; DOXORUBICIN; ETOPOSIDE; FOLINIC ACID; HYDROCORTISONE; METHOTREXATE; VINCRISTINE; ANTINEOPLASTIC AGENT; DACARBAZINE;

ADOLESCENCE; ADOLESCENT; ADULT; ARTICLE; ASCENDING MYELITIS; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CENTRAL NERVOUS SYSTEM; CHILD; DISEASE PREDISPOSITION; DISEASE SEVERITY; GROUPS BY AGE; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; MYELITIS; NEUROTOXICITY; PRESCHOOL CHILD; PRIORITY JOURNAL; PUBERTY; RADIATION DOSE; RADIATION INJURY; RHABDOMYOSARCOMA; SCHOOL CHILD; SPINAL CORD; TREATMENT OUTCOME; CANCER INVASION; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; EWING SARCOMA; FEMALE; GROWTH, DEVELOPMENT AND AGING; INTRASPINAL DRUG ADMINISTRATION; MALE; MENINX; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; RADIATION EXPOSURE; RETROSPECTIVE STUDY; SKULL IRRADIATION; SPINAL CORD TUMOR;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CRANIAL IRRADIATION; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DACTINOMYCIN; ETOPOSIDE; FEMALE; HUMANS; HYDROCORTISONE; INJECTIONS, SPINAL; MALE; MENINGES; METHOTREXATE; MYELITIS; NEOPLASM INVASIVENESS; PUBERTY; RADIATION INJURIES; RETROSPECTIVE STUDIES; RHABDOMYOSARCOMA; SARCOMA, EWING'S; SPINAL CORD; SPINAL NEOPLASMS; VINCRISTINE;

EID: 70449723302     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.22164     Document Type: Article

References (51)

1. Ahlbom H. The results of radiotherapy of hypopharyngeal cancer at the Radiumhemmet, Stockholm, 1930 to 1939. Acta Radiol 1941;22:155-171.
2. Fowler J, Bentzen S, Bond S, et al. Clinical radiation doses for spinal cord: The 1998 international questionnaire. Radiother Oncol 2000;55:295-300.
3. Schultheiss T. Spinal cord radiation tolerance. Int J Radiat Oncol Biol Phys 1994;30:735-736.
4. Kim Y, Fayos J. Radiation tolerance of the cervical spinal cord. Radiology 1981;139:473-478.
5. Benk V, Rodary C, Donaldson S, et al. Parameningeal rhabdomyosarcoma: Results of an international workshop. Int J Radiat Oncol Biol Phys 1996;36:533-540.
6. Meazza C, Ferrari A, Casanova M, et al. Evolving treatment strategies for parameningeal rhabdomyosarcoma: The experience of the Istituto Nazionale Tumori of Milan. Head Neck 2005;27:49-57.
7. Michalski J, Meza J, Breneman J, et al. Influence of radiation therapy parameters on outcome in children treated with radiation therapy for localized parameningeal rhabdomyosarcoma in Intergroup Rhabdomyosarcoma Study Group trials II through IV. Int J Radiat Oncol Biol Phys 2004;59:1027-1038.
8. Paulino A. Role of radiation therapy in parameningeal rhabdomyosarcoma. Cancer Invest 1999;17:223-230.
9. Raney R, Meza J, Anderson J, et al. Treatment of children and adolescents with localized parameningeal sarcoma: Experience of the Intergroup Rhabdomyosarcoma Study Group protocols IRS-II through -IV, 1978-1997. Med Pediatr Oncol 2002;38:22-32.
10. Raney R, Tefft M, Newton W, et al. Improved prognosis with intensive treatment of children with cranial soft tissue sarcomas arising in non-orbital parameningeal sites. Cancer 1987;59:147-155.
11. Raney R, Tefft M, Heyn R, et al. Ascending myelitis after intensive chemotherapy and radiation therapy in children with cranial parameningeal sarcoma. Cancer 1992;69:1498-1506.
12. Ruymann F. Rhabdomyosarcoma in children and adolescents: A review. Hematol/Oncol Clin North America 1987;1:621-654.
13. Packer R, Gurney J, Punyko J, et al. Long-term neurologic and neurosensory sequelae in adult survivors of a childhood brain tumor: Childhood cancer survivor study. J Clin Oncol 2003;21:3255-3261.
14. Abbatucci J, Delozier T, Quint R, et al. Radiation myelopathy of the cervical spinal cord: Time, dose, and volume factors. Int J Radiat Oncol Biol Phys 1978;4:239-248.
15. Baekmark U. Neurologic complications after irradiation of the cervical spinal cord for malignant tumors of the head and neck. Acta Radiat Ther Phys Biol 1975;14:33-41.
16. Jeremic B, Djuric L, Mijatovic L. Incidence of radiation myelitis of the cervical spinal cord at doses of 5500 cGy or greater. Cancer 1991;68:2138-2141.
17. McCunniff A, Liang M. Radiation tolerance of the cervical spinal cord. Int J Radiat Oncol Biol Phys 1989;16:675-678.
18. Phillips TL, Buschke F. Radiation tolerance of the thoracic spinal cord. Am J Roentgenol Radium Ther Nucl Med 1969;105:659-664.
19. van der Kogel A. Radiation tolerance of the rat spinal cord: Time-dose relationships. Radiology 1977;122:505-509.
20. Cohen L, Creditor M. An iso-effect table for radiation tolerance of the human spinal cord. Int J Radiat Oncol Biol Phys 1981;7:961-966.
21. Fein D, Marcus R, Parsons J, et al. Lhermitte's sign: Incidence and treatment variables influencing risk after irradiation of the cervical spinal cord. Int J Radiat Oncol Biol Phys 1993;27:1029-1033.
22. Marcus R, Million R. The incidence of myelitis after irradiation of the cervical spinal cord. Int J Radiat Oncol Biol Phys 1990;19:3-8.
23. Schultheiss T. Radiation "tolerance" of the spinal cord: Doctrine vs. data. Int J Radiat Oncol Biol Phys 1990;19:219-221.
24. Schultheiss T, Stephen L. Permanent radiation myelopathy. Br J Radiol 1992;65:737-753.
25. Nelson R, Frank J. Intrathecal methotrexate-induced neurotoxicities. Am J Hosp Pharm 1981;38:65-68.
26. Ochs J. Neurotoxicity due to central nervous system therapy for childhood leukemia. Am J Pediatr Hematol Oncol 1989;11:93-105.
27. Phantumchinda K, Intragumtornchai T, Kasantikul V. Stroke-like syndrome, mineralizing microangiopathy, and neuroaxonal dystrophy following intrathecal methotrexate therapy. Neurology 1991;41:1847-1848.
28. Resar L, Phillips P, Kastan M, et al. Acute neurotoxicity after intrathecal cytosine arabinoside in two adolescents with acute lymphoblastic leukemia of B-cell type. Cancer 1993;71:117-123.
29. Werner R. Paraplegia and quadriplegia after intrathecal chemotherapy. Arch Phys Med Rehabil 1988;69:1054-1056.
30. Yim Y, Mahoney D, Oshman D. Hemiparesis and ischemic changes of the white matter after intrathecal therapy for children with acute lymphocytic leukemia. Cancer 1991;67:2058-2061.
31. Schwenn M, Blattner S, Lynch E, et al. A 2-month intensive chemotherapy regimen for children with Stage III and IV Burkitt's lymphoma and B-cell acute lymphoblastic leukemia. J Clin Oncol 1991;9:133-138.
32. Ozon A, Haluk T, Cila A, et al. Acute ascending myelitis and encephalopathy after intrathecal cytosine arabinoside and methotrexate in an adolescent boy with acute lymphoblastic leukemia. Brain Dev 1994;16:246-248.
33. Crawford S, Rustin G, Bagshawe K. Acute neurological toxicity of intrathecal cytosine arabinoside: A case report. Cancer Chemother Pharmacol 1986;16:306-307.
34. Kagan A, Bruce D, DiChiro G. Fatal foam cell arteritis of the brain after irradiation for Hodgkin's disease: Angiography and pathology. Stroke 1971;2:232-238.
35. Rottenberg D, Chernik N, Deck M, et al. Cerebral necrosis following radiotherapy of extracranial neoplasms. Ann Neurol 1977;1:339-357.
36. Schultheiss T, Kun L, Ang J, et al. Radiation response of the central nervous system. Int J Radiat Oncol Biol Phys 1995;31:1093-1112.
37. van der Kogel A, Sissingh H. Effects of intrathecal methotrexate and cytosine arabinoside on the radiation tolerance of the rat spinal cord. Radiother Oncol 1985;4:239-251.
38. Bates S, Raphaelson M, Price R, et al. Ascending myelopathy after chemotherapy for central nervous system acute lymphoblastic leukemia: Correlation with cerebrospinal fluid myelin basic protein. Med Pediatr Oncol 1985;13:4-8.
39. Fu K. Biological basis for the interaction of chemotherapeutic agents and radiation therapy. Cancer 1985;55:2123-2130.
40. Packer R, Meadows A, Rorke L, et al. Long-term sequelae of cancer treatment on the central nervous system in childhood. Med Pediatr Oncol 1987;15:241-253.
41. Spector R. Pharmacokinetics and metabolism of cytosine arabinoside in the central nervous system. J Pharmacol Exp Ther 1982;222:1-6.
42. Trott K. Radiation-chemotherapy interactions. Int J Radiat Oncol Biol Phys 1986;12:1409-1413.
43. Pui C, Mahmoud H, Rivera G, et al. Early intensification of intrathecal chemotherapy virtually eliminates central nervous system relapse in children with acute lymphoblastic leukemia. Blood 1998;42:411-415.
44. Goldwein J. Radiation myelopathy: A review. Med Pediatr Oncol 1987;15:89-95.
45. Knowles J. The radiosensitivity of the guinea pig spinal cord to x-rays: The effect of retreatment at one year and the effect of age at the time of irradiation. Int J Radiat Biol 1983;44:433-442.
46. Packer R, Zimmerman R, Bilaniuk L. Magnetic resonance imaging in the evaluation of treatment related central nervous system damage. Cancer 1986;58:635-640.
47. Schultheiss T, Higgins E, El-Mahdi A. The latent period in radiation myelopathy. Int J Radiat Oncol Biol Phys 1984;10:1109-1115.
48. Sundaresan N, Gutierrez F, Larsen M. Radiation myelopathy in children. Ann Neurol 1978;4:47-50.
49. Ruifrok AC, Stephens LC, van der Kogel AJ. Radiation response of the rat cervical spinal cord after irradiation at different ages: Tolerance, latency and pathology. Int J Radiat Oncol Biol Phys 1994;29:73-79.
50. Hamill P, Johnston F, Lemeshow S. Body weight, stature, and sitting height: White and Negro youths 12-17 years. In: Statistics NCfH editor Rockville, MD: DHEW Publication No. (HRA) 74-1608; 1973.
51. Hamill P, Johnston F, Lemeshow S. Height and weight of youths 12-17 years: US Vital and Health Statistics, Series 11, #126. In: Office UGP editor Washington, DC; 1973.